Spruce Biosciences has successfully concluded its pre-Biologics License Application (BLA) meetings with the U.S. Food and Drug Administration (FDA) for its MPS IIIB therapy.

Several companies have announced a range of financial activities, including proposed public offerings of common stock and pre-funded warrants. Additionally, some firms declared quarterly dividends and released previews or results for their first-quarter earnings.

Spruce Biosciences reported a GAAP EPS of -$6.68, and Annexon Biosciences reported a GAAP EPS of -$0.28, missing estimates by $0.04. These reports provide financial updates for the respective companies.

Spruce Biosciences (SPRB) has appointed Dale Hooks as its Chief Commercial Officer and reported a narrowed net loss of $39 million for 2025.

Tyra Biosciences reported a GAAP EPS of -$0.64, while Spruce Biosciences announced a GAAP EPS of -$8.94, missing analyst expectations. These reports provide updates on the companies' financial performance.

Dianthus Therapeutics reported a GAAP EPS of -$1.43, missing estimates by $0.34, and revenue of $0.28M, missing by $0.17M.